Physician profile
Sarah Ali
NPI 1558547588
$6,351.61
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,634 · 2020: $1,994 · 2021: $42.48 · 2022: $371 · 2023: $224 · 2024: $86.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $310.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $1,000.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $850.41 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $765.53 | 2019-2023 | Calquence |
| Merck Sharp & Dohme LLC | $470.26 | 2019-2022 | |
| Janssen Biotech, INC. | $441.87 | 2019-2022 | |
| Genentech USA, INC. | $329.84 | 2019-2022 | |
| Pfizer INC. | $271.18 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $237.93 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $196.03 | 2019-2020 | |
| Clovis Oncology, INC. | $178.46 | 2019-2020 | |
| Eisai INC. | $167.47 | 2019-2020 | |
| Astellas Pharma US INC | $132.14 | 2019-2022 | |
| Genzyme Corporation | $117.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $109.95 | 2019-2020 | |
| Exelixis INC. | $99.28 | 2019-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunogen, INC. | $86.51 | 2024 | Elahere |
| Alexion Pharmaceuticals, INC. | $77.44 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.10 | 2019 | |
| Seagen INC. | $65.66 | 2020-2022 | |
| Foundation Medicine, INC. | $62.91 | 2019-2020 | |
| Puma Biotechnology, INC. | $58.08 | 2019-2020 | |
| Incyte Corporation | $53.05 | 2019-2022 | |
| Amgen INC. | $48.71 | 2019-2020 | |
| Lilly USA, LLC | $46.80 | 2019-2022 | |
| Abbvie INC. | $45.39 | 2019 | |
| Sandoz INC. | $44.96 | 2019 | |
| Verastem, INC. | $35.97 | 2019 | |
| Daiichi Sankyo INC. | $30.49 | 2019 | |
| Celgene Corporation | $29.23 | 2019 | |
| Tesaro, INC. | $29.23 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.55 | 2019 | |
| Gilead Sciences, INC. | $24.07 | 2019 | |
| Glaxosmithkline, LLC. | $23.97 | 2022 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Partner Therapeutics, INC. | $19.12 | 2019 | |
| Sobi, INC | $18.12 | 2022 | |
| Array Biopharma INC | $16.64 | 2019 | |
| Aurobindo Pharma USA, INC. | $15.13 | 2019 | |
| Dova Pharmaceuticals | $13.13 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $12.70 | 2019 | |
| Emd Serono, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.